![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
2. Surufatinib
1. 1308672-74-3
2. Surufatinib
3. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
4. Hmpl-012
5. Kdr-in-1
6. 1816307-67-1
7. Hmpl012
8. Surufatinib [inn]
9. Surufatinib [usan]
10. B2k5l1l8s9
11. N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
12. Benzenemethanesulfonamide, N-(2-(dimethylamino)ethyl)-3-((4-((2-methyl-1h-indol-5-yl)oxy)-2-pyrimidinyl)amino)-
13. Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1h-indol-5-yl)oxy]-2-pyrimidinyl]amino]-
14. Sulanda
15. N-[2-(dimethylamino)ethyl]-1-[3-({4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl}amino)phenyl]methanesulfonamide
16. Sulfatinib [who-dd]
17. Sulfatinib; Hmpl-012
18. Unii-b2k5l1l8s9
19. Surufatinib [who-dd]
20. Gtpl9769
21. Schembl1822601
22. Chembl4297190
23. Bcp14757
24. Ex-a2524
25. Nsc797937
26. Who 10349
27. Akos030632837
28. Zinc117218067
29. Cs-5949
30. Db15106
31. Nsc-797937
32. Ac-35852
33. As-74954
34. Hmpl-012;hmpl 012;hmpl012
35. Hy-12297
36. Vegfr2 Inhibitor [wo2011060746]
37. D71057
38. A926546
39. N-(2-(dimethylamino) Ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide
40. N-(2-(dimethylamino) Ethyl)-1-(3-((4-(2-methyl-1h-indol-5-yloxy) Pyrimidin-2-yl) Amino) Phenyl) Methanesulfonamide
Molecular Weight | 480.6 g/mol |
---|---|
Molecular Formula | C24H28N6O3S |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 10 |
Exact Mass | 480.19435995 g/mol |
Monoisotopic Mass | 480.19435995 g/mol |
Topological Polar Surface Area | 121 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 733 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of haematopoietic and lymphoid tissue